About APT Pharmaceuticals
APT Pharmaceuticals is a drug development company and is looking to extend the reach of stalled specialty drugs, reviving and repurposing them for uses. The development of such drugs, often targeting critical diseases, addresses a huge pharmaceutical industry R&D gap per the company. APT's model aims to allow the company to profitably pursue opportunities that appear too small for larger or less efficient organizations. Furthermore, APT has great flexibility in deal structure, making it an attractive partner. APT aims to improve its probability of success by working with well-characterized drugs that it has identified as promising candidates for further development.
Missing: APT Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: APT Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing APT Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
APT Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
APT Pharmaceuticals Frequently Asked Questions (FAQ)
When was APT Pharmaceuticals founded?
APT Pharmaceuticals was founded in 1999.
Where is APT Pharmaceuticals's headquarters?
APT Pharmaceuticals's headquarters is located at 700 Airport Boulevard, Burlingame.
What is APT Pharmaceuticals's latest funding round?
APT Pharmaceuticals's latest funding round is Series B.
How much did APT Pharmaceuticals raise?
APT Pharmaceuticals raised a total of $85.3M.
Who are the investors of APT Pharmaceuticals?
Investors of APT Pharmaceuticals include Versant Ventures, Vivo Capital, Charter Life Sciences, Great Point Partners, Charter Venture Capital and 6 more.
Who are APT Pharmaceuticals's competitors?
Competitors of APT Pharmaceuticals include Novira Therapeutics, iPierian, Insight Pharmaceuticals, Conatus Pharmaceuticals, Pearl Therapeutics and 10 more.
Compare APT Pharmaceuticals to Competitors
Velbionanotech is designing drugs for various diseases such as Heart Disease, kidney stones, AIDS, Cancer, cosmetic generic products using a short fragment of DNA as a new type of drugs. These drugs are assembled in Nanochips and as nano particals for delivering in human body, which are affective in curing the sick/diseased and healing the injured. nVBN are working into New gene therapy procedures, DNA-based sensors, and other medical applications by using a new method developed to initiate and control chemical reactions on DNA strands. On the other hand silicon-based nanochips with itching and self-assembling techniques used to deliver drugs on the diseased molecules. The company are designing bionano products for the treatment of various diseases for Kidney stones,Gallbladder,Liver, Lungs,Heart etc mixing biology with traditional machinery. VBN Nanomedicine prepared for Heart disease, Galbladder, Liver, Kidney stones will have no side effect and it is safe to use since it is herbal. nn
APT Therapeutics develops acute-use drugs for controlling clot formation in stroke, pulmonary embolism, myocardial infarction, deep vein thrombosis, and transplantation.
Message Pharmaceuticals, Inc. is leveraging its platform technology in developing new classes of drugs that mimic RNA binding proteins to treat all major disease categories.
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.
JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.